These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 36621910)

  • 21. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
    Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults.
    Barrett A; Hahn-Pedersen J; Kragh N; Evans E; Gnanasakthy A
    Patient; 2019 Oct; 12(5):445-459. PubMed ID: 31270775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study.
    Chiricozzi A; Gori N; Narcisi A; Balato A; Gambardella A; Ortoncelli M; Marzano AV; Balestri R; Palazzo G; Pellegrino M; Romanelli M; Tripepi G; Peris K; Costanzo A;
    Drugs R D; 2022 Sep; 22(3):245-252. PubMed ID: 35922713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
    Clabbers J; Boesjes C; Spekhorst L; van Gisbergen MW; Maas E; Marshall J; Janssen R; Janssen M; Zuithoff N; Steijlen P; de Graaf M; van Geel M; de Bruin-Weller M; Gostyński A
    J Allergy Clin Immunol; 2024 Apr; 153(4):1155-1161.e4. PubMed ID: 38272373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
    De Greef A; Ghislain PD; de Montjoye L; Baeck M
    Adv Ther; 2023 May; 40(5):2509-2514. PubMed ID: 36944819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
    Zhang J; Boesjes CM; Loman L; Kamphuis E; Romeijn MLE; Spekhorst LS; Haeck I; van der Gang LF; Dekkers CC; van der Rijst LP; Oosting AJ; van Lumig P; van Lynden-van Nes AMT; Tupker RA; Nijssen A; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; de Graaf M; de Bruin-Weller MS; Schuttelaar MA
    J Am Acad Dermatol; 2024 Aug; 91(2):300-311. PubMed ID: 38653344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.
    Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
    Oosterhaven JAF; Spekhorst LS; Zhang J; Voorberg AN; Romeijn GLE; Boesjes CM; de Graaf M; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatolog Treat; 2022 Jun; 33(4):1986-1989. PubMed ID: 34151695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
    Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.
    Drucker AM; Lam M; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Mohan T; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2024 Sep; 160(9):936-944. PubMed ID: 39018058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
    Simpson EL; Papp KA; Blauvelt A; Chu CY; Hong HC; Katoh N; Calimlim BM; Thyssen JP; Chiou AS; Bissonnette R; Stein Gold LF; Wegzyn C; Hu X; Liu M; Liu J; Tenorio AR; Chu AD; Guttman-Yassky E
    JAMA Dermatol; 2022 Apr; 158(4):404-413. PubMed ID: 35262646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.
    Huang D; Lu J; Tan F
    Dermatitis; 2024; 35(1):77-83. PubMed ID: 37930745
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
    Hagino T; Yoshida M; Hamada R; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2023 Dec; 34(1):2276043. PubMed ID: 38073228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
    Heratizadeh A; Haufe E; Stölzl D; Abraham S; Heinrich L; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach-Renz P; Asmussen A; Schwarz B; Bell M; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Biedermann T; Weidinger S; Schmitt J; Werfel T;
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1263-1272. PubMed ID: 31721316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upadacitinib effectiveness in moderate-to-severe atopic dermatitis: A real-life multicentre and retrospective study.
    Melgosa Ramos FJ; González-Delgado V; Motilla JMS; Marta GP; Mateu Puchades A; Sergio SA
    Australas J Dermatol; 2023 Nov; 64(4):e361-e364. PubMed ID: 37743698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
    Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
    Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting.
    Patruno C; Lauletta G; Pezzolo E; Boccaletti V; Rossi M; Caroppo F; Fortina AB; Russo F; Cocuroccia B; Bello GD; Martora F; di Vico F; Napolitano M
    Clin Drug Investig; 2024 Aug; 44(8):629-634. PubMed ID: 39012535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.